Literature DB >> 17127691

Lack of efficacy of Rituximab in a patient with essential mixed cryoglobulinaemia.

H Cohen, S Green, S Jones, N Amos, B D William.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17127691     DOI： 10.1093/rheumatology/kel387

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  3 in total

1.  Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

Authors:  Hans-Peter Tony; Gerd Burmester; Hendrik Schulze-Koops; Mathias Grunke; Joerg Henes; Ina Kötter; Judith Haas; Leonore Unger; Svjetlana Lovric; Marion Haubitz; Rebecca Fischer-Betz; Gamal Chehab; Andrea Rubbert-Roth; Christof Specker; Jutta Weinerth; Julia Holle; Ulf Müller-Ladner; Ramona König; Christoph Fiehn; Philip Burgwinkel; Klemens Budde; Helmut Sörensen; Michael Meurer; Martin Aringer; Bernd Kieseier; Cornelia Erfurt-Berge; Michael Sticherling; Roland Veelken; Ulf Ziemann; Frank Strutz; Praxis von Wussow; Florian M P Meier; Nico Hunzelmann; Enno Schmidt; Raoul Bergner; Andreas Schwarting; Rüdiger Eming; Michael Hertl; Rudolf Stadler; Michael Schwarz-Eywill; Siegfried Wassenberg; Martin Fleck; Claudia Metzler; Uwe Zettl; Jens Westphal; Stefan Heitmann; Anna L Herzog; Heinz Wiendl; Waltraud Jakob; Elvira Schmidt; Klaus Freivogel; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2011-05-13       Impact factor: 5.156

Review 2.  Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature.

Authors:  Freke Wink; Pieternella M Houtman; Tim L Th A Jansen
Journal:  Clin Rheumatol       Date:  2010-10-31       Impact factor: 3.650

3.  A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab.

Authors:  Semir Pasa; Abdullah Altintas; Timucin Cil; Ramazan Danis; Orhan Ayyildiz; Ekrem Muftuoglu
Journal:  J Thromb Thrombolysis       Date:  2008-01-13       Impact factor: 5.221
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.